Sign In
Buy PSTV
$5.42
-0.0500 (-0.91%)
At Close: Jun 03, 2026
Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
07:00am, Thursday, 03'rd Aug 2023
AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advance
Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
07:00am, Thursday, 13'th Jul 2023
AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advan
Plus Therapeutics to Present at the 2023 Virtual June Investor Summit
07:00am, Thursday, 25'th May 2023
AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanc
Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript
10:30pm, Thursday, 20'th Apr 2023
Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript.
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
07:01pm, Thursday, 20'th Apr 2023
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference
04:15pm, Tuesday, 18'th Apr 2023
AUSTIN, Texas, April 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advance
Plus Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on April 20, 2023
07:00am, Wednesday, 12'th Apr 2023
AUSTIN, Texas, April 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics
Plus Therapeutics, Inc. (PSTV) Q4 2022 Earnings Call Transcript
11:07pm, Thursday, 23'rd Feb 2023
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants Marc Hedrick - President and Chief Executive Officer Norman LaFrance - Chief M
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
06:49pm, Thursday, 23'rd Feb 2023
Plus (PSTV) delivered earnings and revenue surprises of -6.67% and 88.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
07:00am, Tuesday, 14'th Feb 2023
AUSTIN, Texas, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics
Plus Therapeutics, Inc. (PSTV) Q3 2022 Earnings Call Transcript
11:36pm, Thursday, 20'th Oct 2022
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2022 Earnings Conference Call October 20, 2022 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Norman LaFrance - Chief
Plus Therapeutics to Present at the ThinkEquity Conference
07:00am, Tuesday, 18'th Oct 2022
AUSTIN, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and diffic
Best Penny Stocks To Buy? 3 To Watch During The Stock Market Crash
02:16pm, Monday, 10'th Oct 2022
Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?
Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022
07:00am, Thursday, 06'th Oct 2022
AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics
Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
07:00am, Thursday, 08'th Sep 2022
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and diffi
